Stryker's SWOT analysis: medical tech giant eyes growth amid challenges

Stryker (SYK) reported strong Q4 2024 and Q1 2025 results, exceeding expectations with 10.2% organic growth driven by key segments like Hips and Knees; 2025 organic sales growth is now guided at 8.5-9.5%. The $4.9 billion acquisition of Inari Medical expands Stryker's presence in the venous thromboembolism market, while the divestiture of the U.S. spinal implant business aligns with a focus on higher-growth areas, though the Inari deal is expected to dilute EPS by $0.20-$0.30. Despite a $200 million tariff headwind expected in 2025, analysts project continued EPS growth, with estimates of $13.57 for fiscal year 2025 and $15.10 for fiscal year 2026.

Analysis

Stryker Corporation (SYK) is exhibiting robust financial health and strategic execution, underscored by a 10.76% revenue growth over the last twelve months and strong Q4 2024 and Q1 2025 results that exceeded consensus on both revenue and earnings. The company posted impressive 10.2% organic growth in Q4 2024, fueled by significant gains in its Hips and Knees segments (12.2% and 9.5% growth respectively), prompting an upward revision of its 2025 organic sales growth guidance to 8.5-9.5%. Key strategic initiatives include the $4.9 billion acquisition of Inari Medical, positioning Stryker in the rapidly expanding $15 billion global venous thromboembolism (VTE) market, and the divestiture of its U.S. spinal implant business to concentrate on higher-growth opportunities; the Inari deal is projected to be accretive to sales growth but will dilute 2025 EPS by $0.20-$0.30 and slightly impact near-term operating margins. Despite a consistent 35-year dividend payment history and strong performance from its Mako robotic system, Stryker faces a notable $200 million revenue headwind from tariffs in 2025, alongside integration risks related to the Inari acquisition, which also carries uncertainty from an ongoing DOJ investigation into Inari. Analyst EPS projections remain positive at $13.57 for FY2025 and $15.10 for FY2026, though the company's premium forward P/E ratio of approximately 26-27x necessitates careful monitoring of its ability to navigate these challenges and successfully integrate new assets.

Key Decisions for Investors

• Investors should closely track the integration of Inari Medical, particularly its impact on operating margins and the realization of projected synergies, given the acquisition's scale and the near-term EPS dilution.
• It is crucial to assess Stryker's strategies for mitigating the $200 million tariff headwind in 2025 and their potential impact on profitability, alongside the execution of its raised organic sales growth guidance.
• Consider the balance between the significant long-term growth opportunity in the venous thromboembolism market and the acknowledged near-term financial impacts and integration risks when evaluating Stryker's premium valuation.